RxDoctor Payments Data

Janki Shah, MD

Cardiovascular Disease · Santa Monica, CANPI 1497826325

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,582 of the $25,854 with a category attached, or 98.9%. Amgen accounts for 98.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $25,582 and has fallen 99.4% since, to $142 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,854in general payments, 2019–2025

Across 9 payments — averaging $2872.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$26K
  • Heartflow, Inc.$142
  • Abbott$98
  • Baxter Healthcare$33

What the payments were for

  • Consulting fees$25,58299%
  • Food & beverage$2391%
  • Other$330%

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen6$25,582
Heartflow, Inc.1$142
Abbott1$98
Baxter Healthcare1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,854 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024
$587,257
Medicare patients
1,779
Services billed
6,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab257$325,332
XareltoRivaroxaban213$268,342
EliquisApixaban175$241,916
Praluent PenAlirocumab67$68,685
EntrestoSacubitril/Valsartan19$34,327
FarxigaDapagliflozin Propanediol23$33,431
JardianceEmpagliflozin25$27,913
VascepaIcosapent Ethyl24$23,165
Rosuvastatin Calcium835$16,212
Ezetimibe291$12,298
DiovanValsartan18$10,992
Metoprolol Succinate565$10,278
Atorvastatin Calcium718$8,394
Amlodipine Besylate683$6,383
Losartan Potassium438$5,600

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Santa Monica

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →